• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用医疗信息数据库分析意向治疗和方案内效应在安全性结局上的影响:抗生素性肝损伤风险评估中的应用。

Analyzing intent-to-treat and per-protocol effects on safety outcomes using a medical information database: an application to the risk assessment of antibiotic-induced liver injury.

机构信息

a Department of Biostatistics, School of Public Health, Graduate School of Medicine , The University of Tokyo , Tokyo , Japan.

b Department of Healthcare Information Management , The University of Tokyo Hospital , Tokyo , Japan.

出版信息

Expert Opin Drug Saf. 2018 Nov;17(11):1071-1079. doi: 10.1080/14740338.2018.1528224. Epub 2018 Oct 4.

DOI:10.1080/14740338.2018.1528224
PMID:30252549
Abstract

OBJECTIVE

To apply a causal analysis approach to estimate the intent-to-treat and per-protocol effects in a safety outcome study of the 30-day risk of liver injury associated with antibiotic use (macrolides, penicillin-based antibiotics, and fluoroquinolones).

RESEARCH DESIGN AND METHODS

For each antibiotic class, we constructed a pooled cohort of treated episodes matched with untreated episodes using an electronic medical record database from a university hospital. High-dimensional propensity scores were calculated using baseline patient characteristics, concomitant medications and medical history as surrogate confounders. Intent-to-treat hazard ratios (HRs) were estimated using inverse probability of treatment weighted discrete hazard models that ignored subsequent treatment changes. Per-protocol HRs were calculated using inverse probability of treatment and censoring weighted models after terminating each episode's observation at the first treatment change.

RESULTS

For macrolides, the intent-to-treat HR (95% confidence interval) was 1.22 (0.75-1.98) and the per-protocol HR was 1.22 (0.67-2.22). For penicillin-based antibiotics, the intent-to-treat HR was 4.01 (3.16-5.08) and the per-protocol HR was 7.25 (5.58-9.41). For fluoroquinolones, the intent-to-treat HR was 1.60 (1.27-2.03) and the per-protocol HR was 1.69 (1.23-2.30).

CONCLUSION

Researchers should clearly define the target estimands, and carefully estimate and interpret both effects.

摘要

目的

应用因果分析方法估计与抗生素使用相关的 30 天肝损伤风险的安全性结局研究中的意向治疗和方案治疗效果(大环内酯类、青霉素类抗生素和氟喹诺酮类)。

研究设计和方法

对于每种抗生素类别,我们使用来自大学医院的电子病历数据库,将治疗发作的合并队列与未治疗发作的合并队列进行匹配。使用基线患者特征、伴随药物和病史作为替代混杂因素计算高维倾向评分。使用忽略随后治疗变化的逆概率治疗加权离散风险模型估计意向治疗危险比(HR)。使用在每个发作的观察结束时终止第一次治疗变化的逆概率治疗和 censoring 加权模型计算方案治疗 HR。

结果

对于大环内酯类,意向治疗 HR(95%置信区间)为 1.22(0.75-1.98),方案治疗 HR 为 1.22(0.67-2.22)。对于青霉素类抗生素,意向治疗 HR 为 4.01(3.16-5.08),方案治疗 HR 为 7.25(5.58-9.41)。对于氟喹诺酮类,意向治疗 HR 为 1.60(1.27-2.03),方案治疗 HR 为 1.69(1.23-2.30)。

结论

研究人员应明确界定目标估计值,并仔细估计和解释两种效果。

相似文献

1
Analyzing intent-to-treat and per-protocol effects on safety outcomes using a medical information database: an application to the risk assessment of antibiotic-induced liver injury.利用医疗信息数据库分析意向治疗和方案内效应在安全性结局上的影响:抗生素性肝损伤风险评估中的应用。
Expert Opin Drug Saf. 2018 Nov;17(11):1071-1079. doi: 10.1080/14740338.2018.1528224. Epub 2018 Oct 4.
2
Cardiovascular safety of macrolide and fluoroquinolone antibiotics: An analysis of the WHO database of adverse drug reactions.大环内酯类和氟喹诺酮类抗生素的心血管安全性:对世界卫生组织药物不良反应数据库的分析。
Pharmacoepidemiol Drug Saf. 2019 Nov;28(11):1457-1463. doi: 10.1002/pds.4873. Epub 2019 Aug 18.
3
Antibiotic-Induced Liver Injury in Paediatric Outpatients: A Case-Control Study in Primary Care Databases.儿科门诊患者抗生素所致肝损伤:一项基于初级保健数据库的病例对照研究
Drug Saf. 2017 Apr;40(4):305-315. doi: 10.1007/s40264-016-0493-y.
4
Risk of retinal tear or detachment with oral fluoroquinolone use: a cohort study.口服氟喹诺酮类药物使用导致视网膜裂孔或脱离的风险:一项队列研究。
Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):745-52. doi: 10.1002/pds.3623. Epub 2014 Apr 22.
5
Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions.口服抗生素与严重皮肤不良药物反应风险。
JAMA. 2024 Sep 3;332(9):730-737. doi: 10.1001/jama.2024.11437.
6
Concomitant use of statins and macrolide antibiotics and risk of serious renal events: A nationwide cohort study.同时使用他汀类药物和大环内酯类抗生素与严重肾脏事件风险的关系:一项全国性队列研究。
Int J Cardiol. 2018 Oct 15;269:310-316. doi: 10.1016/j.ijcard.2018.06.110. Epub 2018 Jul 30.
7
Semi-automated risk estimation using large databases: quinolones and Clostridium difficile associated diarrhea.利用大型数据库进行半自动化风险评估:喹诺酮类药物与艰难梭菌相关性腹泻。
Pharmacoepidemiol Drug Saf. 2010 Jun;19(6):610-7. doi: 10.1002/pds.1968.
8
Previous antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: results from prospective surveillance.既往抗生素暴露与侵袭性肺炎球菌病的抗菌药物耐药性:前瞻性监测结果。
Clin Infect Dis. 2014 Oct;59(7):944-52. doi: 10.1093/cid/ciu497. Epub 2014 Jun 27.
9
Macrolide and fluoroquinolone mediated cardiac arrhythmias: clinical considerations and comprehensive review.大环内酯类和氟喹诺酮类药物介导的心律失常:临床考量与综述
Postgrad Med. 2017 Sep;129(7):715-724. doi: 10.1080/00325481.2017.1362938. Epub 2017 Aug 10.
10
Antimicrobial use: a risk factor or a protective factor for acquiring campylobacteriosis?抗菌药物使用:是弯曲杆菌病的危险因素还是保护因素?
Clin Infect Dis. 2011 Oct;53(7):644-50. doi: 10.1093/cid/cir504.

引用本文的文献

1
Reporting of Observational Studies Explicitly Aiming to Emulate Randomized Trials: A Systematic Review.旨在模拟随机试验的观察性研究报告:系统评价。
JAMA Netw Open. 2023 Sep 5;6(9):e2336023. doi: 10.1001/jamanetworkopen.2023.36023.
2
Carfilzomib's Real-World Safety Outcomes in Korea: Target Trial Emulation Study Using Electronic Health Records.卡非佐米在韩国的真实世界安全性结局:基于电子健康记录的目标试验模拟研究。
Int J Environ Res Public Health. 2022 Oct 19;19(20):13560. doi: 10.3390/ijerph192013560.
3
Systemic quinolones and risk of acute liver failure III: A nested case-control study using a US electronic health records database.
系统喹诺酮类药物与急性肝衰竭风险 III:一项使用美国电子健康记录数据库的巢式病例对照研究。
J Gastroenterol Hepatol. 2021 Aug;36(8):2307-2314. doi: 10.1111/jgh.15504. Epub 2021 Mar 31.